The Future of CAR T-Cell Therapy in LBCL

News
Video

Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss different uses for CAR T-cell therapy, particularly a trial in which a CAR T-Cell therapy is being evaluated in MRD-positive patients treated with chemotherapy.

Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Chun-Yu Chen, PhD, a research scientist at Seattle Children’s Research Institute
Michael Severino on In Vivo Gene Editing With RNA Gene Writers
Chris Wright, MD, PhD, on Annelloviruses, a Potential Alternative to AAV for Gene Therapy
Carol Miao, PhD, a principal investigator at Seattle Children’s Research Institute
Jacques Galipeau, MD, on Exponential Progress With Cell and Gene Therapy
Carol Miao, PhD, a principal investigator at Seattle Children’s Research Institute
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Related Content
Susan Bal, MD, University of Alabama at Birmingham

Arlo-Cel Generates Excitement, Moves Quickly to Phase 3 Studies for Multiple Myeloma

Silas Inman
December 10th 2024
Article

Arlocabtagene autoleucel shows promise as a potential first in class GPRC5D-targeted CAR T-cell therapy for heavily pretreated multiple myeloma.

Novartis's CAR-T Tisagenlecleucel Continues to Show Efficacy for R/R Follicular Lymphoma in Long-Term Follow-Up

Novartis's CAR-T Tisagenlecleucel Continues to Show Efficacy for R/R Follicular Lymphoma in Long-Term Follow-Up

Jason M. Broderick
December 10th 2024
Article

The CAR-T, marketed as Kymriah, showed a 4-year overall survival rate of 79.3% and a median progression-free survival of 53.3 months.

Allogeneic CAR-NK Therapy TAK-007 Achieves Responses in R/R B-NHL

Allogeneic CAR-NK Therapy TAK-007 Achieves Responses in R/R B-NHL

Noah Stansfield
December 9th 2024
Article

With regard to safety, there were no dose-limiting toxicities, no cases of GvHD, and no cases of TAK-007-related ICANS.

Alexis Thompson, MD, MPH

bluebird bio’s Transfusion-Dependent β-Thalassemia Gene Therapy Beti-Cel Continues to Demonstrate Curative Potential in Long-Term Follow-Up Data

Noah Stansfield
December 9th 2024
Article

Protocol-defined transfusion independence (TI) was achieved by 52 of the 63 patients in long-term follow-up study LTF-303.

stem cell

Allogeneic Hematopoietic Stem Cell Transplantation Replicates Posititve Outcomes in Transfusion-Dependent Thalassemia

Matt Hoffman
December 8th 2024
Article

Allo-HSCT showed good 2-year survival data, with matched sibling donors showing superior outcomes to alternative donors.

Alaa Ali, MD, from the Lombardi Comprehensive Cancer Center, Georgetown University

Bendamustine Is an Effective Alternative to Fludarabine-Based Lymphodepletion in LBCL

Silas Inman
December 7th 2024
Article

In the wake of fludarabine shortages, lemphodepletion with bendamustine was found to be an effective alternative compared for patients with large B-cell lymphoma being treated with a CD19-directed CAR T-cell therapy.

© 2024 MJH Life Sciences

All rights reserved.